BBNX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
32.0M
+15.9%
27.6M
-14.0%
32.1M
+17.9%
27.3M
+17.3%
23.2M
Cost of Revenue
13.1M
+17.2%
11.2M
-15.1%
13.2M
+8.6%
12.1M
+13.0%
10.7M
Gross Profit
18.9M
+15.0%
16.4M
-13.2%
18.9M
+25.3%
15.1M
+20.9%
12.5M
Operating Expenses
44.5M
+9.3%
40.7M
+16.1%
35.1M
+9.0%
32.2M
-0.7%
32.4M
R&D
10.2M
-1.1%
10.4M
+2.2%
10.1M
+23.6%
8.2M
-7.6%
8.9M
SG&A
34.2M
+12.8%
30.4M
+21.7%
24.9M
+4.0%
24.0M
+2.0%
23.5M
Operating Income
-25578000
-5.4%
-24271000
-50.5%
-16124000
+5.4%
-17043000
+14.2%
-19872000
EBITDA
-24869000
-5.0%
-23686000
-52.0%
-15586000
+6.4%
-16658000
+14.7%
-19525000
Net Income
-23403000
-6.9%
-21895000
-62.6%
-13466000
+5.2%
-14209000
+15.8%
-16869000
EPS (Basic)
$-0.53
-8.2%
$-0.49
-63.3%
$-0.30
+9.1%
$-0.33
+15.4%
$-0.39
EPS (Diluted)
$-0.53
-8.2%
$-0.49
-63.3%
$-0.30
+9.1%
$-0.33
+15.4%
$-0.39
Shares (Diluted)
44.5M
+0.2%
44.4M
+0.1%
44.4M
+1.7%
43.6M
+0.6%
43.4M
Beta Bionics (BBNX) โ€” Financials